NYSE$SYK
Stryker Corp · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Stryker's Q4 2020 results reflected resilience amidst COVID-19 challenges, with net sales increasing by 3.2% and adjusted EPS rising by 12.9%.
Stryker reported a 3.2% increase in net sales to $4.3 billion for Q4 2020. Despite challenges from the COVID-19 pandemic, the company's adjusted EPS increased by 12.9% to $2.81. The Wright Medical integration is off to a strong start, and innovation continues across the company.
- Net sales increased 3.2% to $4.3 billion.
- Organic net sales decreased 1.1%.
- Adjusted EPS increased 12.9% to $2.81.
- The Wright Medical integration is off to a strong start.
Headline financials
Revenue & EPS history
Stryker · Revenue · Quarterly
$4.26B
Revenue by segment
Stryker · $3.38B total across 2 segments · Q4 2020
- MedSurg and Neurotechnology$1.85B+0.9%54.9%
- Orthopaedics$1.53B+4.0%45.1%
Forward guidance
Stryker expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019 and adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
Tailwinds
- Expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019
- Expects adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
- Includes the previously announced 10 cents of dilution driven by the acquisition of Wright Medical for the full year.
- Assumes an ongoing recovery in our key geographies leading to more normalized elective procedure levels during the second quarter of 2021.
- Expect EPS will be modestly favorable for the full year if foreign currency exchange rates hold near current levels.
Headwinds
- The impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties
- Unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright
- Weakening of economic conditions that could adversely affect the level of demand for our products
- Pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products
- Potential supply disruptions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.7%
Avg return
30 days after
58%
42 / 73 earnings
Positive
+11.8%
Q4 2022
Best reaction
-6.3%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.4% | -7.2% | -3.0% | |
| Q4 2025 | +2.6% | +1.8% | +9.4% | |
| Q3 2025 | -3.0% | -3.1% | +0.6% | |
| Q2 2025 | +0.0% | -0.4% | +3.6% | |
| Q1 2025 | +1.0% | +2.7% | +2.3% | |
| Q4 2024 | -2.2% | -2.2% | -2.8% | |
| Q3 2024 | +2.1% | +3.1% | +9.0% | |
| Q2 2024 | -1.7% | -0.5% | +7.4% | |
| Q1 2024 | -3.2% | -3.1% | +0.5% | |
| Q4 2023 | +6.7% | +8.8% | +11.0% | |
| Q3 2023 | +1.5% | +1.1% | +9.5% | |
| Q2 2023 | +3.3% | +2.8% | +3.6% | |
| Q1 2023 | -1.9% | -5.0% | -8.0% | |
| Q4 2022 | +11.8% | +13.5% | +5.0% | |
| Q3 2022 | -4.0% | -8.0% | +2.0% | |
| Q2 2022 | +5.1% | +6.6% | +7.5% | |
| Q1 2022 | -3.2% | -4.5% | -5.1% | |
| Q4 2021 | +0.1% | +0.1% | +7.1% | |
| Q3 2021 | -0.9% | +1.5% | -9.3% | |
| Q2 2021 | +2.0% | +2.8% | +2.9% | |
| Q1 2021 | -2.1% | -1.0% | -4.1% | |
| Q4 2020 | -3.4% | -4.8% | +2.0% | |
| Q3 2020 | -1.4% | +1.6% | +13.6% | |
| Q2 2020 | -4.0% | -6.0% | -1.6% | |
| Q1 2020 | -6.3% | -2.5% | +1.6% | |
| Q4 2019 | -1.8% | -1.8% | -9.2% | |
| Q3 2019 | +1.6% | -0.4% | -4.1% | |
| Q2 2019 | +0.4% | +0.0% | +0.2% | |
| Q1 2019 | +1.6% | +3.4% | +1.3% | |
| Q4 2018 | +10.7% | +9.5% | +16.4% | |
| Q3 2018 | -1.7% | -0.7% | +1.0% | |
| Q2 2018 | -2.7% | -3.2% | -3.0% | |
| Q1 2018 | +3.2% | +2.2% | +5.1% | |
| Q4 2017 | -2.6% | -3.9% | -5.6% | |
| Q3 2017 | +6.4% | +3.1% | +3.0% | |
| Q2 2017 | +1.4% | +1.5% | -4.0% | |
| Q1 2017 | +1.3% | +1.4% | +4.8% | |
| Q4 2016 | -0.2% | +3.3% | +3.6% | |
| Q3 2016 | +4.0% | +4.5% | +2.7% | |
| Q2 2016 | -4.4% | -4.8% | -7.0% | |
| Q1 2016 | -0.4% | — | — | |
| Q4 2015 | +4.4% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2014 | -0.2% | — | — | |
| Q1 2014 | -1.1% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2013 | +2.7% | — | — | |
| Q2 2013 | +2.2% | — | — | |
| Q1 2013 | +1.1% | — | — | |
| Q4 2012 | +2.8% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | -2.9% | — | — | |
| Q1 2012 | +2.2% | — | — | |
| Q4 2011 | -0.0% | — | — | |
| Q3 2011 | -2.9% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2011 | +0.2% | — | — | |
| Q4 2010 | +1.9% | — | — | |
| Q3 2010 | +2.3% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2009 | -1.1% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q4 2009 | +1.9% | — | — | |
| Q4 2007 | +1.9% | — | — | |
| Q3 2008 | +2.9% | — | — | |
| Q3 2009 | +2.9% | — | — | |
| Q2 2009 | +5.1% | — | — | |
| Q2 2008 | +5.1% | — | — | |
| Q4 2008 | +5.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro